Literature DB >> 31373855

Blocking the histone lysine 79 methyltransferase DOT1L alleviates renal fibrosis through inhibition of renal fibroblast activation and epithelial-mesenchymal transition.

Lirong Liu1,2, Jianan Zou1, Yingjie Guan1, Yunhe Zhang1, Wei Zhang1, Xiaoxu Zhou1, Chongxiang Xiong1, Evelyn Tolbert1, Ting C Zhao3, George Bayliss1, Shougang Zhuang1,4.   

Abstract

Disruptor of telomeric silencing-1 like (DOT1L) protein specifically catalyzes the methylation of histone H3 on Lys79 (H3K79) and is implicated in tumors. But its role in tissue fibrosis remains unclear. Here we demonstrated that injury to the kidney increased DOT1L expression and H3K79 dimethylation in renal tubular epithelial cells and myofibroblasts in a murine model of unilateral ureteral obstruction. Administration of EPZ5676, a highly selective inhibitor of DOT1L, attenuated renal fibrosis. Treatment with EPZ5676 or DOT1L small interfering RNA also inhibited TGF-β1 and serum-induced activation of renal interstitial fibroblasts and epithelial-mesenchymal transition (EMT) in vitro. Moreover, blocking DOT1L abrogated injury-induced epithelial G2/M arrest; reduced expression of Snail, Twist, and Notch1; and inactivated several profibrotic signaling molecules in the injured kidney, including Smad3, epidermal growth factor receptor, platelet-derived growth factor receptor, signal transducer and activator of transcription 3, protein kinase B, and NF-κB. Conversely, DOT1L inhibition increased expression of phosphatase and tensin homolog, a protein associated with dephosphorylation of tyrosine kinase receptors, and prevented decline in levels of Klotho and Smad7, 2 renoprotective factors. Thus, our data indicate that targeting DOT1L attenuates renal fibrosis through inhibition of renal fibroblasts and EMT by suppressing activation of multiple profibrotic signaling pathways while retaining expression of renoprotective factors.-Liu, L., Zou, J., Guan, Y., Zhang, Y., Zhang, W., Zhou, X., Xiong, C., Tolbert, E., Zhao, T. C., Bayliss, G., Zhuang, S. Blocking the histone lysine 79 methyltransferase DOT1L alleviates renal fibrosis through inhibition of renal fibroblast activation and epithelial-mesenchymal transition.

Entities:  

Keywords:  ERSD; Notch1; Smad3; Snail; transforming growth factor

Mesh:

Substances:

Year:  2019        PMID: 31373855      PMCID: PMC8793787          DOI: 10.1096/fj.201801861R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  53 in total

Review 1.  Klotho as a potential biomarker and therapy for acute kidney injury.

Authors:  Ming-Chang Hu; Orson W Moe
Journal:  Nat Rev Nephrol       Date:  2012-06-05       Impact factor: 28.314

Review 2.  Molecular mechanisms and therapeutic strategies of chronic renal injury: the role of nuclear factor kappaB activation in the development of renal fibrosis.

Authors:  Satoshi Tamada; Toshihiro Asai; Nobuyuki Kuwabara; Tomoaki Iwai; Junji Uchida; Kae Teramoto; Noriko Kaneda; Tokihito Yukimura; Toshiyuki Komiya; Tatsuya Nakatani; Katsuyuki Miura
Journal:  J Pharmacol Sci       Date:  2006-01-06       Impact factor: 3.337

3.  Loss of tumour suppressor PTEN expression in renal injury initiates SMAD3- and p53-dependent fibrotic responses.

Authors:  Rohan Samarakoon; Sevann Helo; Amy D Dobberfuhl; Nidah S Khakoo; Lucas Falke; Jessica M Overstreet; Roel Goldschmeding; Paul J Higgins
Journal:  J Pathol       Date:  2015-04-27       Impact factor: 7.996

4.  Sunitinib induces PTEN expression and inhibits PDGFR signaling and migration of medulloblastoma cells.

Authors:  Thamara J Abouantoun; Robert C Castellino; Tobey J MacDonald
Journal:  J Neurooncol       Date:  2010-06-04       Impact factor: 4.130

Review 5.  Renal tubule injury: a driving force toward chronic kidney disease.

Authors:  Bi-Cheng Liu; Tao-Tao Tang; Lin-Li Lv; Hui-Yao Lan
Journal:  Kidney Int       Date:  2018-01-17       Impact factor: 10.612

Review 6.  Emerging roles of lysine methylation on non-histone proteins.

Authors:  Xi Zhang; Yaling Huang; Xiaobing Shi
Journal:  Cell Mol Life Sci       Date:  2015-07-31       Impact factor: 9.261

7.  Snail1-induced partial epithelial-to-mesenchymal transition drives renal fibrosis in mice and can be targeted to reverse established disease.

Authors:  M Teresa Grande; Berta Sánchez-Laorden; Cristina López-Blau; Cristina A De Frutos; Agnès Boutet; Miguel Arévalo; R Grant Rowe; Stephen J Weiss; José M López-Novoa; M Angela Nieto
Journal:  Nat Med       Date:  2015-08-03       Impact factor: 53.440

8.  Inhibition of H3K9 histone methyltransferase G9a attenuates renal fibrosis and retains klotho expression.

Authors:  Taisuke Irifuku; Shigehiro Doi; Kensuke Sasaki; Toshiki Doi; Ayumu Nakashima; Toshinori Ueno; Kyoko Yamada; Koji Arihiro; Nobuoki Kohno; Takao Masaki
Journal:  Kidney Int       Date:  2016-01-04       Impact factor: 10.612

9.  DOT1L-HES6 fusion drives androgen independent growth in prostate cancer.

Authors:  Matti Annala; Kati Kivinummi; Katri Leinonen; Joonas Tuominen; Wei Zhang; Tapio Visakorpi; Matti Nykter
Journal:  EMBO Mol Med       Date:  2014-09       Impact factor: 12.137

Review 10.  Role of Receptor Tyrosine Kinase Signaling in Renal Fibrosis.

Authors:  Feng Liu; Shougang Zhuang
Journal:  Int J Mol Sci       Date:  2016-06-20       Impact factor: 5.923

View more
  14 in total

1.  Systemic Immune-Inflammation Index Predicts Overall Survival in Patients with Gastric Cancer: a Propensity Score-Matched Analysis.

Authors:  Noriyuki Hirahara; Yoshitsugu Tajima; Takeshi Matsubara; Yusuke Fujii; Shunsuke Kaji; Yasunari Kawabata; Ryoji Hyakudomi; Tetsu Yamamoto; Yuki Uchida; Takahito Taniura
Journal:  J Gastrointest Surg       Date:  2020-06-30       Impact factor: 3.452

2.  Histone methyltransferase DOT1L mediates the TGF-β1/Smad3 signaling pathway through epigenetic modification of SYK in myocardial infarction.

Authors:  Fei Li; Lei Li; Jiacheng Zhang; Xuesong Yang; Yang Liu
Journal:  Hum Cell       Date:  2021-10-11       Impact factor: 4.174

Review 3.  Epigenetic modifications of Klotho expression in kidney diseases.

Authors:  Jinkun Xia; Wangsen Cao
Journal:  J Mol Med (Berl)       Date:  2021-02-06       Impact factor: 4.599

Review 4.  Tackle Epithelial-Mesenchymal Transition With Epigenetic Drugs in Cancer.

Authors:  Bo Dong; Zhaoping Qiu; Yadi Wu
Journal:  Front Pharmacol       Date:  2020-11-27       Impact factor: 5.810

5.  Identification of microRNA-Associated-ceRNA Networks Regulating Crop Milk Production in Pigeon (Columba livia).

Authors:  Pingzhuang Ge; Hui Ma; Yunlei Li; Aixin Ni; Adamu Mani Isa; Panlin Wang; Shixiong Bian; Lei Shi; Yunhe Zong; Yuanmei Wang; Linlin Jiang; Hailai Hagos; Jingwei Yuan; Yanyan Sun; Jilan Chen
Journal:  Genes (Basel)       Date:  2020-12-30       Impact factor: 4.096

6.  DOT1L inhibition enhances pluripotency beyond acquisition of epithelial identity and without immediate suppression of the somatic transcriptome.

Authors:  Coral K Wille; Rupa Sridharan
Journal:  Stem Cell Reports       Date:  2022-01-06       Impact factor: 7.765

7.  Blocking the histone lysine 79 methyltransferase DOT1L alleviates renal fibrosis through inhibition of renal fibroblast activation and epithelial-mesenchymal transition.

Authors:  Lirong Liu; Jianan Zou; Yingjie Guan; Yunhe Zhang; Wei Zhang; Xiaoxu Zhou; Chongxiang Xiong; Evelyn Tolbert; Ting C Zhao; George Bayliss; Shougang Zhuang
Journal:  FASEB J       Date:  2019-08-02       Impact factor: 5.191

Review 8.  Protective factors as biomarkers and targets for prevention and treatment of diabetic nephropathy: From current human evidence to future possibilities.

Authors:  Natalia Nowak
Journal:  J Diabetes Investig       Date:  2020-05-06       Impact factor: 4.232

Review 9.  Histone Methyltransferases as Therapeutic Targets for Kidney Diseases.

Authors:  Chao Yu; Shougang Zhuang
Journal:  Front Pharmacol       Date:  2019-12-06       Impact factor: 5.810

Review 10.  New Insights Into the Role and Mechanism of Partial Epithelial-Mesenchymal Transition in Kidney Fibrosis.

Authors:  Lili Sheng; Shougang Zhuang
Journal:  Front Physiol       Date:  2020-09-15       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.